Intech Investment Management LLC Has $1.67 Million Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Intech Investment Management LLC lifted its holdings in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 160.4% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 88,661 shares of the biotechnology company’s stock after buying an additional 54,616 shares during the period. Intech Investment Management LLC owned about 0.07% of Arrowhead Pharmaceuticals worth $1,667,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of ARWR. State Street Corp raised its holdings in shares of Arrowhead Pharmaceuticals by 8.8% during the 3rd quarter. State Street Corp now owns 6,354,331 shares of the biotechnology company’s stock worth $123,083,000 after buying an additional 516,569 shares in the last quarter. Edgestream Partners L.P. bought a new stake in Arrowhead Pharmaceuticals during the 4th quarter worth $2,264,000. Fisher Asset Management LLC grew its position in Arrowhead Pharmaceuticals by 941.0% during the 3rd quarter. Fisher Asset Management LLC now owns 122,260 shares of the biotechnology company’s stock worth $2,368,000 after acquiring an additional 110,516 shares during the last quarter. Wealthfront Advisers LLC bought a new stake in Arrowhead Pharmaceuticals during the 4th quarter worth $2,060,000. Finally, King Luther Capital Management Corp bought a new stake in Arrowhead Pharmaceuticals during the 4th quarter worth $1,447,000. Institutional investors and hedge funds own 62.61% of the company’s stock.

Insider Activity at Arrowhead Pharmaceuticals

In related news, Director Adeoye Y. Olukotun sold 2,850 shares of the company’s stock in a transaction that occurred on Friday, December 27th. The stock was sold at an average price of $20.00, for a total transaction of $57,000.00. Following the transaction, the director now directly owns 36,740 shares of the company’s stock, valued at approximately $734,800. This represents a 7.20 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Christopher Richard Anzalone sold 12,563 shares of the company’s stock in a transaction that occurred on Monday, December 23rd. The stock was sold at an average price of $19.59, for a total value of $246,109.17. Following the transaction, the chief executive officer now directly owns 3,775,772 shares in the company, valued at approximately $73,967,373.48. This trade represents a 0.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 301,730 shares of company stock worth $5,352,844 in the last 90 days. Corporate insiders own 4.30% of the company’s stock.

Arrowhead Pharmaceuticals Trading Down 2.1 %

NASDAQ ARWR opened at $14.80 on Friday. Arrowhead Pharmaceuticals, Inc. has a 12 month low of $14.23 and a 12 month high of $30.41. The company has a current ratio of 6.09, a quick ratio of 6.09 and a debt-to-equity ratio of 7.27. The business’s 50-day moving average price is $18.58 and its two-hundred day moving average price is $19.92. The firm has a market capitalization of $2.03 billion, a PE ratio of -2.86 and a beta of 0.92.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its earnings results on Monday, February 10th. The biotechnology company reported ($1.39) EPS for the quarter, missing the consensus estimate of ($0.42) by ($0.97). On average, analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. StockNews.com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a research report on Friday, December 20th. Piper Sandler reduced their price objective on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 27th. Chardan Capital restated a “buy” rating and set a $60.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. HC Wainwright restated a “buy” rating and set a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th. Finally, B. Riley restated a “buy” rating and set a $38.00 price objective (down previously from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. One analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $41.44.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.